Rethinking a hybrid malaria chemoprevention delivery strategy for children in sub-perennial settings: integrating age- and seasonally-targeted delivery
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulphadoxine-pyrimethamine (SP) to children at high risk of severe P. falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as ‘sub-perennial’. Tailored chemoprevention strategies are needed to protect children during seasons and ages of highest malaria risk. The seasonal dimension must adequately cover seasonally increased risk periods, alongside interventions that address year-round, lower intensity transmission. We propose a hybrid malaria chemoprevention (HMC) strategy, integrating two delivery components: 1) existing PMC, and 2) additional monthly SP doses during the higher-risk rainy season, ensuring a one-month gap between any two doses.
Methods
Using a validated individual-based malaria model combined with pharmacological models of drug action (OpenMalaria), we examined the potential public health impact of the proposed HMC (for children 03-24 months), and an age-expanded HMC (referred to as HMC+, for children 03-36 months), under different drug sensitivity, coverage, and prevalence (5-70%) assumptions.
Results
HMC and HMC+ demonstrated a median (interquartile range) of 2.1 (1.6–2.6), 2.9 (2.2-3.6) times higher efficacy (relative fold increase in burden averted) compared to only PMC against clinical, and 2.0 (0.6–3.4), 3.3 (0.8-5.8) against severe cases, respectively, in children under age three. This led to a median protective efficacy of 31.8% (25.4-38.2%), 44.9% (36.9-52.9%) against clinical, and 16.1% (7.0-25.2%), 26.4% (14.4-38.4%) against severe cases by HMC and HMC+ respectively, across the prevalence, drug sensitivity, and coverage assumptions. We found positive net impact for children under age five years, outweighing a limited potential of delayed malaria across settings.
Conclusion
Substantially increased public health benefits might be achieved by adding seasonally-targeted chemoprevention to current PMC in sub-perennial malaria transmission settings. Effectiveness-implementation studies should generate empirical evidence of public health impact including on the disease burden averted, safety, and cost-effectiveness of the hybrid approach. Such studies should also explore determinants of implementation success including operational feasibility, and acceptability of proposed dosing strategies which will facilitate deployment decisions.
